CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Signia Therapeutics has developed a drug discovery platform that identifies antimicrobial compounds targeting infected cells rather than pathogens. This innovative approach aims to accelerate the development of broad-spectrum antimicrobials, addressing the urgent need for effective treatments against drug-resistant inf…
The economic and social burden of infections is being enhanced by the emergence of drug-resistant pathogens.
This phenomenon is outpacing the industry’s capacity for drug discovery and development.
Antimicrobial resistance is costing the EU today €1.5 billion and 25,000 deaths annually.
Developing de novo classical drugs is very costly and time consuming, and for every new drug released a resistant strain has rapidly emerged.
This paradigm is hindering our ability to respond to outbreaks.
Among…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
